【word】 CATT研究：兰尼单抗与贝伐珠单抗的“判决书”

【word】 CATT研究：兰尼单抗与贝伐珠单抗的“判决书” CATT研究:兰尼单抗与贝伐珠单抗的“判 决书” 脂质体肺部给药的应用进展 【8】VyasSP,KannanME,JainSY,eta1.Designoflipo— somalaerosolsforimproveddeliveryofrifampicinto alveolarmacrophage~-J]./ntJ2004_,269(137—49. [9】LeJ,SchillerDS.AerosolizedDeliveryofAntifungal Agents[J].CurrFungalInfectRep,2010,4(2):96102. 【10】VyasSP,QuraishiS,GuptaS,eta1.Aerosolizedlipo— some—baseddeliveryofamphotericinBtoalveolar macrophages[J]./ntJnr,n,2005,296(1—21:12—25. 【11】BriscoeP,CaniggiaI,GravesA,eta1.Deliveryof superoxidedismutasetopulmonaryepitheliumviapH- sensitiveliposomes[J].AmJPhysiol,1995,2680):L374- 8 【12】WijagkanalanW,KawakamiS,HiguchiY,eta1.In— tratraeheallyinstilledmannosylatedcationicliposome/ NFKBdecoycomplexesforeffectivepreventionof LPS-inducedlunginflammationJControlledRelease, 2010,ArticleinPress,CorrectedProof. [13JShahSP,MisraA.LiposomalAmikacinDryPowder InhMenEfieetofFinesonInVitroPerformancelJ1. AAPSPharmSciTech,2004,5(4):e65. 【14】OkusanyaOO,BhavnaniSM,HammelJ,eta1.Phar- maeokineticandPharmacodynamicEvaluationofLipo— somalAmikacinforInhaLationinCysticFibrosisPa— tientswithChronicPseudomonalInfection【JlAntimicrob AgentsChemother,2009Sep,53(9):384754. [151ShahiwalaA,MisraA.APreliminaryPharmacokinetic StudyofLiposomalLeuprolideDryPowderInhaler:A TechnicalNoteAAPSPharmSciTech,2005,6 E482-6. [16】BaiS,GuptaV,AhsanF.Cationicliposomesascar— riersforaerosolizedformulationsofananionicdrug: Safetyandefficacystudy[J].EurJmSci.2009.38 f21:165—71. [17]AudouySA,deLeijLF,HoekstraD.Invivocharac— teristicsofcationicliposomesasdeliveryvectorsfor genetherapy[J].Res,2002,19(II):1599—605. [18】张莉,景年水,李云霞,等.脂质体肺部给药的研究 进展[J1.中国医院药学杂志,2008.28(17):1496—8. [19】DokkaS,ToledoD,ShiX,eta1.Oxygenradical—me— diatedpulmonarytoxicityinducedbysoniccationicli— posomes[J].PharmRes,2000,l7(5):52l一5. [20】CryanSA.Carrier—basedStrategiesfi)rTargetingPro— teinandPeptideDrugstotheLungs[J1.AA2005, 7f11:E20—41. ApplicationandDevelopmentofLiposomeFormulationinPulmonaryDelivery WANGYan,TANGYue,LUXi-~ng,ZHUJia-bi SchoolofPharmacy,ChinaPharmaceuticalUniversity,Nanjing21000~China ABSTRACTTheliposome—mediatedpulmonarydrugdeliveryasanon—i nvasiveadministration.makes drugslocatedatthesiteofactiontotreatpulmonarydiseasesdirectly.reducesextrapulmonaryside—effects avoidsthehepaticfirstpasseffect,increasesthebioavailabilityandavoidsfrequentadministrationasthe double—layeroftheliposomecanincreasetheretention—time.Therelateda dvantageoftheliposome— mediatedpulmonarydrugdeliveryandthewayofadministrationaremainlyintroducedinthisreview.We alsosummarizedtheresearchanddevelopmentoftherelevantliposomesathomeandabroad.beingused toworkthroughpulmonarypathway,asthecarriersofantiinflammatoryanda nti-infectivedrugs, antioxidants,antasthmatics,antitumordrugs,antithromboticsandsoon. KEYWORDSLiposome;Pulmonarydelivery;Carrier;Nebulize;Neinhale; Safety 近5年来,患者和临床医生在两种治疗新生血管性 老年黄斑变性(AMD)药物的选择上一直纠结不清.AMD 主要由黄斑内血管的异常增生和渗漏所引起.抗血管内 皮生长因子(WGF)重复注入眼内可抑制VEGF活性,进 而可在大多数患者中预防失明. 贝伐珠单抗和兰尼单抗为两种最常用的抗VEGF药 物,前者被FDA批准用于治疗某些癌症,后者则被批准 用于治疗眼部疾病.由于两种药物存在治疗费用差异(前 者每剂仅需50美元,后者则需2000美元)和临床疗效相 似性,贝伐珠单抗在缺少I类证据的情况下仍被广泛使用. 为了进?步明确两者对澌生血管性AMD的治疗效果, 美国国家卫生研究院(NIH)资助了一项关于上述两种药物 治疗方案的大规模临床研究(CATT),研究结果4月28日 在线发于《新英格兰医学杂志.研究表明,1年时贝伐殊单 抗和兰尼单抗对AMD患者视辙度改善效果相等. 美国迈阿密大学米勒医学院罗斯菲尔德(Rosenfeld) 博士在同期述评中亦明确指出,CATT研究结果以及全球 总体经验支持贝伐珠单抗或兰尼单抗用于治疗新生血管 性AMD.目前需要对应用兰尼单抗高额费用的正当性加 以明确.作为兰尼单抗的替代药物,廉价有效的贝伐珠单 抗应继续在全球范围内应用. (来源:中国医学论坛报2011-06-07)